Figure 5.

Anti-Leukemic Efficacy of TM123-Redirected UniCAR-T Is Comparable to CD123 CAR-T

(A) A CD123-specific CAR construct including a fixed binding moiety was constructed by replacing the UniCAR binding domain with the single-chain fragment variable (scFv) of the CD123-specific TM. (B) CD123 CAR-T as well as UniCAR-T (2 × 10⁴) in the presence or absence of 5 nM TM123 were cultivated with OCI-AML3 cells at an e:t ratio of 1:1. Degranulation of CAR-T and UniCAR-T was determined by CD107a expression after 6 h of culture. (C) Cytotoxic efficacy of CD123 CAR-T (n = 3) and UniCAR-T (n = 5) in combination with 5 nM TM123 against OCI-AML3 cells (5 × 10⁴) was determined after 24 and 48 h for the indicated range of e:t ratios and compared to control samples containing tumor cells only (gray bars). Statistical significance was assessed for indicated numbers of donors by non-parametric one-way analysis of variance (Kruskal-Wallis test) with Dunn’s multiple comparison test (B) or a non-parametric Wilcoxon-Mann-Whitney test (C) (∗p ≤ 0.05; ns, not significant).